Focused Oral Presentations: ORIGIN 3 Subgroup Analysis, PIONEER IgAN Preliminary Findings, and ORIGIN Extend Off-Treatment (cd3f01)

Vera Therapeutics Inc. published this content on June 05, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 24, 2026 at 05:53 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]